NCT07895927

Toxicity of Intensive First-Line Treatment for Adult Burkitt Lymphoma: A Retrospective Observational Study

RecruitingOBSERVATIONAL

Trial Details

Start: 2026-02-11Est. Completion: 2027-02-11

Enrollment target: 25 participants

Locations

Service d'Hématologie et d'Oncologie - CHU de Strasbourg, France, Strasbourg, France

Contact

Marie-Pierre LEDOUX, MDmariepierre.ledoux@chru-strasbourg.fr 33 3 68 76 74 07

Other microbiome trials you might be interested in

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)Phase 2Recruiting

B Acute Lymphoblastic Leukemia

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemothe…

Birmingham, United StatesEst. completion Dec 1, 2030

View Trial →

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic LeukemiaPhase 1Recruiting

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin LymphomaB-Cell Prolymphocytic LeukemiaHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedPost-Transplant Lymphoproliferative Disorder

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.